Philadelphia

Area Biotech Company Testing 2 Products to Fight Ebola Virus

Hemispherx Biopharma said Monday it has reached an agreement with a unit of the Department of Defense to test two of its products for their potential effectiveness against the Ebola virus.

No financial terms of the agreement were disclosed.

The studies involving Alfernon and Ampligen will be conducted at the USAMRIID’s Laboratories at Fort Detrick in Maryland.

USAMRID is the Department of Defense unit responsible for medical biological defense research.

Alfernon is Philadelphia-based Hemispherx’s lone product in the market. It is an interferon drug approved as a treatment for genital warts. Interferon is a protein released by body, usually in response to the entry of a virus, to block a virus from replicating. Read more about this story on PBJ.com.

For more breaking business news go to PBJ.com

Copyright bizjournal
Contact Us